Please note that following on from information provided to NICE by the company in January 2012, the appraisal of Pralatrexate for the treatment of relapsed or refractory peripheral T-cell lymphoma [ID368] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
Status | Discontinued |
Decision | Selected |
Process | TA |
Referral date | 01 September 2010 |
Topic area |
|
Description |
Scoped within Batch 13 |
Provisional Schedule
Closing date for invited submissions / evidence submission: | 18 January 2012 |
1st appraisal committee meeting: | TBC |
2nd appraisal committee meeting | TBC |
Project Team
Communications manager: | Alice Law |
Executive Lead: | Peter Littlejohns |
Project manager: | Rebecca Pye |
Technical Lead: | Pall Jonsson |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
23 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in January 2012, the appraisal of Pralatrexate for the treatment of relapsed or refractory peripheral T-cell lymphoma [ID368] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
17 February 2012 | Following an update on the regulatory status of the technology which has received a negative CHMP opinion, the 25 April 2012 committee meeting discussion for this appraisal has been cancelled. We are monitoring this situation and will provide an update as soon as possible. |
1 December 2011 | We have received the latest regulatory timings for pralatrexate from the manufacturer, Allos Therapeutics, and are now able to update our timelines for the above appraisal. The first committee meeting will be held on 25 April 2012. |
13 July 2011 |
Following an update from the manufacturer, Allos Therapeutics, on the regulatory timings for pralatrexate the 27 September 2011 committee meeting discussion for the above appraisal has been cancelled. We will update this page with the new timings as soon as possible. |
For further information on our processes and methods, please see our CHTE processes and methods manual